[1]
|
S. M. Cockfield, “Identifying the Patient at Risk for Post-Transplant Lymphoproliferative Disorder,” Transplant infectious Disease, Vol. 3, No. 2, 2001, pp. 70-78.
doi:10.1034/j.1399-3062.2001.003002070.x
|
[2]
|
D. A. Thorley-Lawson and A. Gross, “Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas,” The New England Journal of Medicine, Vol. 350, No. 13, 2004, pp. 1328-1337.
doi:10.1056/NEJMra032015
|
[3]
|
L. L. Laichalk and D. A. Thorley-Lawson, “Terminal Differentiation into Plasma Cells initiates the Replicative Cycle of Epstein-Barr Virus in Vivo,” Journal of Virology, Vol. 79, No. 2, 2005, pp. 1296-1307.
doi:10.1128/JVI.79.2.1296-1307.2005
|
[4]
|
V. Hadinoto, M. Shapiro, C. C. Sun, et al., “The Dynamics of EBV Shedding Implicate A Central Role for Epithelial Cells in Amplifying Viral Output,” PLoS Pathogens, Vol. 5, No. 7, 2009, p. 1.
|
[5]
|
A. D. Hislop, G. S. Taylor, D. Sauce, et al., “Cellular Responses to Viral infection in Humans: Lessons from Epstain-Barr Virus,” Annual Reviews of Immunology, Vol. 25, No. 1, 2007, pp. 587-617.
doi:10.1146/annurev.immunol.25.022106.141553
|
[6]
|
A. B. Rickinson and E. Kieff, “Epstein-Barr Virus,” In: D. M. Knipe and P. M. Howley, Eds., Fields Virology, Lippincott Williams & Wilkins, Philadelphia, 2001, pp. 2575-2627.
|
[7]
|
M. Majewski, M. Korecka, P. kossev, et al., “The Immunosuppressive Macrolide RAD Inhibits Growth of Human Epstein-Barr Virus-Transformed B Lymphocytes in Vitro and in Vivo: A Potential Approach to Prevention and Treatment of Posttransplant Lym-phoproliferative Disorders,” Proceedings of the National Academy of Sciences, Vol. 97, No. 8, 2000, pp. 4285-4290
|
[8]
|
S. Muthukkumar, T. M. Ramesh and S. Bondada, “Ra- pamycin, a Potent Immunosuppressive Drug, Causes Programmed Cell Death in B Lymphoma Cells,” Transplantation, Vol. 60, No. 3, 1995, pp. 264-270.
doi:10.1097/00007890-199508000-00010
|
[9]
|
S. N. Seghal, J. S. Camardo, J. A. Scarola, et al., “Rapamycin (Sirolimus, Rapamune),” Current Opinion in Nephrology and Hypertension, Vol. 4, No. 6, 1995, pp. 482-487. doi:10.1097/00041552-199511000-00004
|
[10]
|
T. Hol-moy, “Vitamin D Status Modulates the Immune Response to Epstein Barr Virus: Synergistic Effect of Risk Factors in Multiple Sclerosis,” Medical Hypotheses, Vol. 70, No. 1, 2008, pp. 66-69.
doi:10.1016/j.mehy.2007.04.030
|
[11]
|
Y. Dror, M. Greenberg, G. Taylor, et al., “Lymphoprolif- erative Disorders after Organ Transplantation in Children,” Transplantation, Vol. 67, No. 7, 1999, pp. 990-998.
doi:10.1097/00007890-199904150-00010
|
[12]
|
R. Shapiro, M. Nalesnik, J. Mc Cauley, et al., “Posttrans- plant Lymphoproliferative Disorders in Adult and Pediatric Renal Transplant Patients Receiving Tacrolimus-Based Immunosuppression,” Transplantation, Vol. 68, No. 12, 1999, pp. 1851-1854.
doi:10.1097/00007890-199912270-00006
|
[13]
|
B. S. Younes, S. V. Mc Diarmid, M. G. Martin, et al., “The Effect of Immunosuppression on Posttransplant Lym-phoproliferative Disease in Pediatric Liver Transplant Patients,” Transplantation, Vol. 70, No. 1, 2000, pp. 94-99.
|
[14]
|
J. K. Preiksaitis and S. Keay, “Diagnosis and Management of Post-Transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients,” Clinical Infectious Diseases, Vol. 33, No. S1, 2001, pp. S38-S46.
|
[15]
|
C. E. Kew, R. Lopez-Ben and J. K. Smith, “Posttrans- plant Lymphoproliferative Disorder Localized near the Allograft in Renal Transplantation,” Transplan-tation, Vol. 69, No. 5, 2000, pp. 809-814.
|
[16]
|
P. T. Liu, S. Stenger, H. Y. Li, et al., “Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response,” Science, Vol. 311, No. 5768, 2006, pp. 1770-1773.
|